Milbemycin Oxime,Praziquantel Micronized

Verify with FDA CVM →

137 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
137
Total Reports
3
Deaths Reported
220.0%
Death Rate

Active Ingredients

Milbemycin Oxime,Praziquantel Micronized

Administration Routes

OralUnknownTopical

Species Affected

Dog 136
Unknown 1

Most Affected Breeds

Retriever - Labrador 14
Crossbred Canine/dog 10
Retriever - Golden 10
Shepherd Dog - Australian 8
Shepherd Dog - German 7
Dog (unknown) 7
Beagle 7
Terrier - Bull - American Pit 6
Dachshund (unspecified) 5
Collie - Border 5

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 46
Vomiting 19
Lack of efficacy (endoparasite) - hookworm 14
Diarrhoea 14
Lack of efficacy (endoparasite) - tapeworm 12
Lack of efficacy (endoparasite) - roundworm NOS 8
Lethargy (see also Central nervous system depression in Neurological) 7
Elevated alanine aminotransferase (ALT) 6
Collapse NOS (see also Cardio-vascular and Neurological disorders) 5
Not eating 5
Lack of efficacy (bacteria) - Borrelia 4
Seizure NOS 4

Outcome Breakdown

Outcome Unknown
85 (62.5%)
Recovered/Normal
25 (18.4%)
Ongoing
23 (16.9%)
Euthanized
3 (2.2%)

Data Summary

Metric Value
Total adverse event reports 137
Reports involving death 3
Case-fatality rate (reported events) 220.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin Oxime,Praziquantel Micronized Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 137 adverse event reports referencing Milbemycin Oxime,Praziquantel Micronized, including 3 reports in which the animal died — a 220.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin Oxime,Praziquantel Micronized. Reported administration routes include Oral, Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin Oxime,Praziquantel Micronized reports are Dog (136 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (14), Crossbred Canine/dog (10), Retriever - Golden (10) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin Oxime,Praziquantel Micronized are Lack of efficacy (endoparasite) - heartworm (46), Vomiting (19), Lack of efficacy (endoparasite) - hookworm (14), Diarrhoea (14). Of the 136 reports with a coded outcome, Outcome Unknown is the leading category at 62.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin Oxime,Praziquantel Micronized.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial